TRIVOLIB 1 MG TAB

1. All Details:

Specifications Active Pharmaceutical Ingredients: Glimepiride IP , Voglibose IP , and Metformin Hydrochloride IP as extended release).Dosage Form: Uncoated bilayered tablet.Coloring Agents: Black Oxide of Iron.Storage Environment: Store at room temperature, protected from light and moisture.Regulatory Classifications: * SCHEDULE H PRESCRIPTION DRUG – CAUTION: Not to be sold by retail without the prescription of a Registered Medical Practitioner.SCHEDULE G PRESCRIPTION DRUG – CAUTION: It is dangerous to take this preparation except under medical supervision.Clinical Warning: Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only.Batch Identification: B.No. ZFC0032.Date of Manufacture (MFG. DATE): 02/2025.Date of Expiration (EXPIRY DATE): 01/2028.Maximum Retail Price (M.R.P.): ₹ 265.00 per 15 Tablets (Inclusive of all taxes).Manufacturing License Number (M.L.): 4/UA/LL/2014.Internal Material Reference: 20259392.

2. General Information

Brand: TRIVOLIB® 1 (stylized as TRIVOLIB® 1).Name: Glimepiride, Voglibose and Extended Release Metformin Hydrochloride Tablets.Quantity: Strip of 15 Tablets (indicated by “FOR 15 TABS.” on the stamped margins).Type: Prescription Triple-Combination Oral Anti-Diabetic Medication.Factor (Form Factor): Solid oral tablet (Bilayered formulation design).Maximum Shelf Life: 35 months (From February 2025 to January 2028).Food Preference: Not Applicable. As a critical chemical prescription medication, standard consumer dietary icons (such as vegetarian green dots) are not utilized.FSSAI: Not Applicable. This therapeutic formula is strictly governed under the Drugs and Cosmetics Act by the CDSCO. It is an intensive anti-diabetic drug rather than a health supplement, meaning it does not fall under the purview or licensing of the FSSAI (Food Safety and Standards Authority of India).

3. Product Details:

Ingredients Each uncoated bilayered tablet contains: Glimepiride IP: Voglibose IP: Metformin Hydrochloride IP:\ (as extended release)Excipients: q.s. (Quantity Sufficient)

4. Directions:

How to UseDosage: As directed by the Physician.Administration Instructions: The tablet must be swallowed whole with water. It is typically prescribed to be taken immediately before or with your first primary meal of the day. Crucial Rule: The tablet must not be chewed or crushed. Crushing or chewing would destroy the intentional extended-release matrix of the Metformin layer, leading to unsafe rapid absorption of the active drug.

5. Description

Trivolib 1 is a multi-action oral blood-glucose-lowering treatment formulated for patients managing Type 2 Diabetes Mellitus when standard mono or dual-drug therapies fail to provide sufficient glycemic controls. The tablet uses a structured bilayered design to release three clinical ingredients through distinct path mechanics: Glimepiride (a sulfonylurea that stimulates pancreatic beta cells to produce more insulin), Voglibose (an alpha-glucosidase inhibitor that delays carbohydrate digestion to reduce post-meal sugar spikes), and Metformin Hydrochloride Extended-Release (a biguanide that improves peripheral insulin sensitivity and cuts down liver glucose output consistently over time). The packaging features dual red regulatory warning blocks indicating it contains both Schedule G and Schedule H active compounds, alongside a Registered Trade Mark indicator.

6. Manufacturer Information Manufactured in India by: Akums Drugs & Pharmaceuticals Ltd.Plant Address: At: Plot No. 26A, 27-30, Sector-8A, I.I.E., SIDCUL, Ranipur, Haridwar-249 403, (Uttarakhand).

7. Marketed By: (Akums corporate network distribution controls), ensuring production oversight and systematic commercial logistics.